المؤلفون: Guy Storme, Carmel Lino Cutajar, Michel Bolla, Jean Bernard Dubois, René-Olivier Mirimanoff, Raphael Pfeffer, Cora N. Sternberg, Ignace Billiet, Jacques Bernier, Laurence Collette, Theodore H. van der Kwast, Geertjan van Tienhoven, Padraig Warde, José Lopez Torecilla, Abraham Kuten

المساهمون: Medical Imaging and Physical Sciences, Centre for Oncology, Translational Radiation Oncology and Physics, CCA -Cancer Center Amsterdam, Radiotherapy

المصدر: lancet oncology, 11(11), 1066-1073. Lancet Publishing Group

مصطلحات موضوعية: Male, Time Factors, Cyproterone Acetate/administration & dosage, Kaplan-Meier Estimate, Prostatic Neoplasms/pathology, Androgen suppression, Russia, Fractures, Bone, chemistry.chemical_compound, Prostate cancer, Adenocarcinoma/secondary, Antineoplastic Combined Chemotherapy Protocols, Clinical endpoint, Israel, Dose Fractionation, Goserelin, Antineoplastic Combined Chemotherapy Protocols/adv, risk assessment, Cyproterone acetate, Cardiovascular Diseases/chemically induced, Europe, Treatment Outcome, Oncology, Cardiovascular Diseases, Chemotherapy, Adjuvant, Lymphatic Metastasis, Adenocarcinoma/mortality, Prostatic Neoplasms/drug therapy, medicine.drug, Canada, medicine.medical_specialty, Fractures, Bone/chemically induced, Urology, Adenocarcinoma, Disease-Free Survival, Drug Administration Schedule, Adenocarcinoma/drug therapy, medicine, Humans, Neoplasm Invasiveness, Cyproterone Acetate, Androgen Antagonists/administration & dosage, Prostatic Neoplasms/mortality, Neoplasm Staging, Performance status, business.industry, Goserelin Acetate, Dose fractionation, Prostatic Neoplasms, Androgen Antagonists, Adenocarcinoma/radiotherapy, medicine.disease, Goserelin/administration & dosage, Antineoplastic Combined Chemotherapy Protocols/the, Prostatic Neoplasms/radiotherapy, Surgery, chemistry, Dose Fractionation, Radiation, business

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::20538cc7113223eeb34861a476d18d39
https://doi.org/10.1016/s1470-2045(10)70223-0